A recent Toronto Star article delved into the implications of the newly introduced Bill C-64, which lays down the groundwork for the first phase of a national universal pharmacare system in Canada. The bill outlines the Canadian Government’s intent to collaborate with provinces and territories to provide universal, single-payer coverage for a number of contraception and diabetes medications. Patrick Fafard, GSL Research Director of Public Health Institutions, was quoted providing insights on the potential limitations of the bill regarding its enforceability. Dr. Fafard highlighted concerns about the permissive language within the legislation, suggesting that it may not provide adequate safeguards against future government actions.
Previous